The successful completion of the Human Genome Project signals a new age in medical discovery centered on protein research. The rapidly growing knowledge base of the human genome provides an unprecedented opportunity to launch a revolutionary paradigm for drug discovery based on protein analysis.

NewLink Genetics remains steadfast in its primary focus to take novel treatments and diagnostics through the clinical trials process and bringing products to market. The company is currently conducting Phase I/II clinical trials with its proprietary HyperAcute® vaccine technology. The Food and Drug Administration has accepted NewLink Genetics’ Investigational New Drug applications for the HyperAcute® vaccine technology allowing us to proceed with clinical trials treating patients with advanced lung cancer, prostate cancer, pancreatic cancer, and malignant melanoma. All of our vaccine trials (lung, prostate, pancreatic, and malignant melanoma) are currently enrolling patients at various trial centers. Patients and physicians that are interested in the HyperAcute® clinical trials should directly contact the research coordinator at the trial centers or call our clinical trials office at (515) 296-35331.